Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Howard A. Ball"'
Autor:
Tianhong Li, Patricia LoRusso, Michael L. Maitland, Sai-Hong Ignatius Ou, Erkut Bahceci, Howard A. Ball, Jung Wook Park, Geoffrey Yuen, Anthony Tolcher
Publikováno v:
Journal of Hematology & Oncology, Vol 9, Iss 1, Pp 1-9 (2016)
Abstract Background ASP3026 is a second-generation anaplastic lymphoma kinase (ALK) inhibitor that has potent in vitro activity against crizotinib-resistant ALK-positive tumors. This open-label, multicenter, first-in-human phase I study ( NCT01284192
Externí odkaz:
https://doaj.org/article/6df78f3e3340454c8deb3c23b520004a
Autor:
Andrew Krivoshik, Anne Keating, Howard A. Ball, Chip Van Sant, Jihong Chen, Sandra Vossen, Carolyn Sasse, Ferry A.L.M. Eskens, John Bridgewater, Igor Kiss, Al B. Benson
Patient Disposition
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01105bff1777c1397f541eae29d56c27
https://doi.org/10.1158/1078-0432.22465994.v1
https://doi.org/10.1158/1078-0432.22465994.v1
Autor:
Andrew Krivoshik, Anne Keating, Howard A. Ball, Chip Van Sant, Jihong Chen, Sandra Vossen, Carolyn Sasse, Ferry A.L.M. Eskens, John Bridgewater, Igor Kiss, Al B. Benson
Purpose: Tivozanib, a selective inhibitor of VEGFR-1, -2, and -3, plus mFOLFOX6 in an advanced gastrointestinal cancer phase Ib study had encouraging antineoplastic activity and a tolerable safety profile. This randomized, open-label, phase II trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bd2433571458a2c7b1177e742d38e04
https://doi.org/10.1158/1078-0432.c.6526211
https://doi.org/10.1158/1078-0432.c.6526211
Autor:
Andrew Krivoshik, Anne Keating, Howard A. Ball, Chip Van Sant, Jihong Chen, Sandra Vossen, Carolyn Sasse, Ferry A.L.M. Eskens, John Bridgewater, Igor Kiss, Al B. Benson
Baseline Patient Characteristics: Serum Biomarker Analysis Group
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67acba28d794ce23e2eea8934ce3ef20
https://doi.org/10.1158/1078-0432.22465991.v1
https://doi.org/10.1158/1078-0432.22465991.v1
Autor:
Filip Janku, Jennifer Sugg, Aaron S. Mansfield, Howard A. Ball, Alexander I. Spira, Rita Nanda, Patricia LoRusso, Amal Melhem-Bertrandt, Tianli Wang
Publikováno v:
Investigational new drugs. 39(5)
Background We assessed the safety, tolerability, and pharmacokinetics of mitochondrial complex 1 inhibitor ASP4132. Methods This phase I dose-escalation/dose-expansion study enrolled patients with treatment refractory advanced solid tumors to assess
Autor:
Noboru Yamamoto, Toshihiko Doi, Howard A. Ball, Musashi Fukuda, Masatoshi Kudo, Chia-Chi Lin, Diarmuid M. Moran, Junji Furuse, Bhumsuk Keam, Kentaro Takeda, Futoshi Kunieda, Baek Yeol Ryoo, Kanji Komatsu, Satoshi Morita
Publikováno v:
Investigational new drugs. 38(2)
ASP5878 is a selective small-molecule inhibitor of fibroblast growth factor receptors (FGFRs). This study investigated safety, tolerability, and antitumor effect of single and multiple oral doses of ASP5878 in patients with solid tumors. This phase 1
Autor:
Al B. Benson, John Bridgewater, Igor Kiss, Jihong Chen, Carolyn Sasse, Sandra Vossen, Andrew Krivoshik, Ferry A.L.M. Eskens, Howard A. Ball, Anne Keating, Charles Van Sant
Publikováno v:
Clinical Cancer Research, 22(20), 5058-5067. American Association for Cancer Research Inc.
Purpose: Tivozanib, a selective inhibitor of VEGFR-1, -2, and -3, plus mFOLFOX6 in an advanced gastrointestinal cancer phase Ib study had encouraging antineoplastic activity and a tolerable safety profile. This randomized, open-label, phase II trial
Autor:
Howard A. Ball, Mohammed M. Dar, David R. Spigel, A. Benjamin Suttle, Shelby D. Gainer, Antoinette R. Tan, Howard A. Burris, Diana Lindquist, Jeffrey R. Infante, Kelly Levinson, Suzanne F. Jones, Afshin Dowlati, Rebecca A. Moss
Publikováno v:
Molecular Cancer Therapeutics. 11:1820-1828
Several phase III trials have shown that the addition of an antiangiogenic agent to conventional chemotherapy can improve clinical benefit in patients with advanced solid tumors. This study examined the feasibility of combining pazopanib (Votrient),
Autor:
Howard J. Ball
Publikováno v:
Journal of the American Society for Naval Engineers. 38:789-824
Publikováno v:
Clinical Reviews in Allergy & Immunology. 27:207-218
Advances in our understanding of asthma pathogenesis and delineation of the human genome project are yielding novel candidate targets for therapeutic intervention. In parallel with target identification, the past decade has produced novel approaches